image description

Press Releases

Press Releases

April 2, 2019
Revance to Participate in the Needham Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare
March 5, 2019
Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor
February 26, 2019
Revance Releases Fourth Quarter and Full Year 2018 Results
-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed- -On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019- -Raised approximately $108 million net proceeds from public stock offering on January 22, 2019 -
January 22, 2019
Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total 115.0 Million NEWARK, Calif. --(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today
January 17, 2019
Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 17, 2019-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public
January 15, 2019
Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 15, 2019-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public
Displaying 11 - 20 of 173